Levi & Korsinsky Notifies Reckitt Benckiser Group plc Investors of a Class Action Lawsuit and Upcoming Deadline – RBGLY

(Other OTC:RBGLY), NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc (“Reckitt Benckiser Group plc” or the “Company”) (OTCQX: RBGLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reckitt Benckiser Group plc investors who were adversely […]

Levi & Korsinsky Notifies Reckitt Benckiser Group plc Investors of a Class Action Lawsuit and Upcoming Deadline – RBGLY

Levi & Korsinsky Notifies Reckitt Benckiser Group plc Investors of a Class Action Lawsuit and Upcoming Deadline – RBGLY GlobeNewswire July 28, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc (“Reckitt Benckiser Group plc” or the “Company”) (OTCQX: RBGLY) of a class action

Commercial National Financial Corporation Reports 2nd Quarter 2025 Results

(PinkSheets:CEFC),(Pinksheets:CEFC), ITHACA, Mich., July 28, 2025 (GLOBE NEWSWIRE) — Commercial National Financial Corporation (OTCID: CEFC) reported net income for the second quarter of 2025 of $1,607,000 or $0.41 per share compared to second quarter 2024 net income of $1,412,000 or $0.36 per share. Return on Equity was 12.36% for the second quarter of 2025 compared

Commercial National Financial Corporation Reports 2nd Quarter 2025 Results

Commercial National Financial Corporation Reports 2nd Quarter 2025 Results GlobeNewswire July 28, 2025 ITHACA, Mich., July 28, 2025 (GLOBE NEWSWIRE) — Commercial National Financial Corporation (OTCID: CEFC) reported net income for the second quarter of 2025 of $1,607,000 or $0.41 per share compared to second quarter 2024 net income of $1,412,000 or $0.36 per share.

Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action – ANRO

(NYSE:ANRO), NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (“Alto Neuroscience, Inc.” or the “Company”) (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities

Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action – ANRO

Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action – ANRO GlobeNewswire July 28, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (“Alto Neuroscience, Inc.” or the “Company”) (NYSE: ANRO) of a class action securities lawsuit.

Contact Levi & Korsinsky by September 8, 2025 Deadline to Join Class Action Against XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP(XIFR)

(NYSE:XIFR), NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP (“XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP” or the “Company”) (NYSE: XIFR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of XPLR

Contact Levi & Korsinsky by September 8, 2025 Deadline to Join Class Action Against XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP(XIFR)

Contact Levi & Korsinsky by September 8, 2025 Deadline to Join Class Action Against XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP(XIFR) GlobeNewswire July 28, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP (“XPLR Infrastructure, LP f/k/a Nextera Energy

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

(NasdaqGM:RCKT), SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) — When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw

3D Systems Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. August 12, 2025 Deadline to file Lead Plaintiff Motion

(NYSE:DDD), Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 28, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises 3D Systems Corporation (“3D Systems” or the “Company”) (NYSE: DDD) investors of a class action representing investors that bought securities between August 13, 2024 and

Scroll to Top